Please assess the completion status of the following clinical trial:

Trial Title: Iron Status and Hypoxic Pulmonary Vascular Responses

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give informed consent for participation in the study~* Men and women aged 18 years or older and generally in good health~* Detectable tricuspid regurgitation on echocardiography during both normoxia and hypoxia enabling measurement of pulmonary arterial pressure~* For iron-deficient volunteers: ferritin ≤15microg/L and transferrin saturation \<16%~* For iron-replete volunteers: ferritin ≥20microg/L and transferrin saturation ≥20%~Exclusion Criteria:~* Haemoglobin \<8.0g/dl~* Haemoglobinopathy~* Iron overload defined as ferritin \>300microg/L~* Hypoxia at rest or on walking (SaO2 \<94%) or significant comorbidity that may affect haematinics, pulmonary vascular or ventilatory responses, e.g. current infection, a chronic inflammatory condition, known cardiovalvular lesion or pulmonary hypertension, uncontrolled asthma or chronic obstructive pulmonary disease~* Exposure to high altitude (\>2,500m) within the previous six weeks or air travel \>4 hours within the previous week~* Iron supplementation or blood transfusion within the previous 6 weeks~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Iron-deficient (Type: OTHER): Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
- Iron-replete (Type: OTHER): Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures

Based on this trial design, predict the completion outcome and termination type (if applicable).